Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests
Authors:
- Diego O. AndreyDADiego O. Andrey
- Patrick CohenPCPatrick Cohen
- Benjamin MeyerBMBenjamin Meyer
- Giulia TorrianiGTGiulia Torriani
- Sabine YerlySYSabine Yerly
- Lena MazzaLMLena Mazza
- Adrien CalameACAdrien Calame
- Isabelle Arm-VernezIAIsabelle Arm-Vernez
- Idris GuessousIGIdris Guessous
- Silvia StringhiniSSSilvia Stringhini
- Pascale Roux-LombardPRPascale Roux-Lombard
- Lionel FontaoLFLionel Fontao
Open Access
- 24 July 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2369
Abstract
Background: Comparative data of SARS-CoV-2 IgM/IgG serology rapid diagnostic tests (RDTs) is scarce. We thus performed a head-to-head comparison of three RDTs. Methods: In this unmatched case-control study, blood samples from 41 RT-PCR-confirmed COVID-19 cases and 50 negative controls were studied. The diagnostic accuracy of three commercially available COVID-19 RDTs: NTBIO (RDT-A), Orient-Gene (RDT-B), and MEDsan (RDT-C), against both a recombinant spike-expressing immunofluorescence assay (rIFA) and Euroimmun IgG ELISA, was assessed. RDT results concordant with the reference methods, and between whole blood and plasma, were established by the Kendall coefficient. Results: COVID-19 cases’ median time from RT-PCR to serology was 22 days (interquartile range (IQR) 13–31 days). Whole-blood IgG detection with RDT-A, -B, and -C showed 0.93, 0.83, and 0.98 concordance with rIFA. Against rIFA, RDT-A sensitivity (SN) was 92% (95% CI: 78–98) and specificity (SP) 100% (95% CI: 91–100), RDT-B showed 87% SN (95% CI: 72–95) and 98% SP (95% CI: 88–100), and RDT-C 100% SN (95% CI: 88–100) and 98% SP (95% CI: 88–100). Against ELISA, SN and SP were above 90% for all three RDTs. Conclusions: RDT-A and RDT-C displayed IgG detection SN and SP above 90% in whole blood. These RDTs could be considered in the absence of routine diagnostic serology facilities.Keywords
This publication has 20 references indexed in Scilit:
- Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease PatientsEmerging Infectious Diseases, 2020
- Laboratory Diagnosis of COVID-19: Current Issues and ChallengesJournal of Clinical Microbiology, 2020
- Performance of VivaDiag COVID‐19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID‐19 in acute patients referring to emergency room departmentJournal of Medical Virology, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosisJournal of Medical Virology, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological studyThe Lancet Infectious Diseases, 2015
- Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infectionsEurosurveillance, 2012
- Capillary whole blood measurement of islet autoantibodies.Diabetes Care, 1999
- The Measurement of Observer Agreement for Categorical DataBiometrics, 1977